NDA 215007 · Nexair LLC
Carbon Dioxide, Usp
Carbon Dioide · Inhalation · Radiographic Contrast Agent
Last checked: Nov 19, 2026Latest source record: Jul 18, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jul 18, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
115
109 serious, 14 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 21, 2026.
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 18, 2020 Original approval Letter
1 products under this application
- CARBON DIOXIDE, USP · CARBON DIOIDE N/A · GAS, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Carbon Dioide" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- air embolism32
- subcutaneous emphysema20
- off label use16
- post procedural complication9
- cardiac arrest8
- hypotension7
- pneumoperitoneum7
- hypercapnia6
- drug administration error5
- pco2 increased5
- pneumomediastinum5
- intestinal ischaemia4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 2 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 12 |
| 2014 | 11 |
| 2015 | 6 |
| 2016 | 13 |
| 2017 | 5 |
| 2018 | 27 |
| 2019 | 8 |
| 2020 | 6 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Nexair LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.